Nonetheless, we could argue that the results presented in this manuscript add useful information regarding the interactions between NPM1 and TET2/IDH1/2/WT1 mutations and the correlations that RUNX1 presents could lead to a better understanding of myeloid differentiation and, potentially, the formation of novel AML subtypes that would be treated in a personalized manner. The gene discussed is NPM1; the disease is acute myeloid leukemia.